Extrahepatic perfusion and incomplete hepatic perfusion after hepatic arterial infusion pump implantation: incidence and clinical implications
Wills F. Filipe(Erasmus MC Cancer Institute), Koert F.D. Kuhlmann(The Netherlands Cancer Institute), Roel J. Bennink(Amsterdam University Medical Centers), Paul Harmsen(Erasmus MC Cancer Institute), Rutger‐Jan Swijnenburg(Amsterdam University Medical Centers), J. Sven D. Mieog(Leiden University Medical Center), Jan Willem B. de Groot(Isala), Marnix G. E. H. Lam(University Medical Center Utrecht), Bas Groot Koerkamp, Mark A. Meier(Isala), Gijs A. Patijn(Isala), Pascal G. Doornebosch(IJsselland Ziekenhuis), Tineke E. Buffart(Amsterdam University Medical Centers), Daphne D. D. Rietbergen(Amsterdam University Medical Centers), Otto M. van Delden(Amsterdam UMC Location University of Amsterdam), Laura H. Graven(Erasmus MC), Stijn Franssen(Erasmus MC Cancer Institute), Ad H. Oostdijk(Isala), Loubna Outmani(Utrecht University), Karen Bolhuis(The Netherlands Cancer Institute), Florian E. Buisman(Erasmus MC), Dirk J. Grünhagen(Erasmus MC), Marjolein Y.V. Homs(Erasmus MC Cancer Institute), Jeroen Hagendoorn(Utrecht University), Florian Buismanz Buisman(Erasmus MC Cancer Institute), Jeanine M.L. Roodhart(University Medical Center Utrecht), Myrtle F. Krul(The Netherlands Cancer Institute), Michelle W.J. Versleijen(The Netherlands Cancer Institute), O. J. L. Loosveld(Amphia Ziekenhuis), Mark C. Burgmans(Leiden University Medical Center), Niels F.M. Kok(The Netherlands Cancer Institute)
Cited by 3
Related Papers
Cholangiocarcinoma 2020: the next horizon in mechanisms and management
|Nature Reviews Gastroenterology & Hepatology|2020|2.5k
Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial
|Journal of Clinical Oncology|2020|1.1k
Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2018|1k
FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis
|The Lancet Oncology|2016|914
The PD-1/PD-L1-Checkpoint Restrains T cell Immunity in Tumor-Draining Lymph Nodes
|Cancer Cell|2020|683